Novomedix LLC
San Diego, CA
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 7966 Arjons Dr Ste D, San Diego, CA 92126, USA
- Website
- novomedix.com
- Founded
- 2001
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $2,977,013 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Traverse Biotech II Inc. | New York, NY | — |
| Celdara Medical, LLC | Lebanon, NH | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Business | Del Mar, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mtti | West Chester, PA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Faknostics LLC | Phoenix, AZ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Novomedix LLC, a woman-owned small business based in San Diego, California, develops novel oral small-molecule therapeutics for fibrotic and oncologic diseases and operates exclusively as a prime recipient of federal research grants and SBIR contracts from National Institutes of Health components, with no subcontractor footprint.
Novomedix is structured as a limited liability partnership and holds a woman-owned small business (WOSB) designation. The company's federal work concentrates entirely on investigator-initiated research and Small Business Innovation Research awards under total small business set-asides, competing in full-and-open pools restricted to small businesses rather than seeking broader competitive vehicles. Its portfolio spans 14 awards across four NIH institutes over the past five years.
The company's capability portfolio centers on preclinical and early-stage therapeutic development using small-molecule compounds targeting fibrotic pathways and cardiotoxicity. Representative work includes a $2,977,013 SBIR Phase II contract awarded by the National Cancer Institute on September 15, 2025, to develop enhanced overall survival therapies in high-risk pediatric solid tumors using a novel oral small molecule (ultimate completion September 14, 2027); a $355,963 Project Grant from the National Heart, Lung, and Blood Institute awarded September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for novel small-molecule anti-fibrotic compounds targeting Duchenne muscular dystrophy cardiomyopathy; and a $314,362 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded September 22, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for small-molecule inhibitors of interleukin-11 to treat arthrofibrosis.
Customer concentration is highly concentrated within NIH. The National Heart, Lung, and Blood Institute accounts for six awards and drives the majority of grant funding. The National Cancer Institute holds two awards worth $3.3 million in combined potential value (100% of current dollar ceiling across the portfolio). The National Institute of Arthritis and Musculoskeletal and Skin Diseases and broader NIH programs account for the remainder. All fourteen awards are prime grants and contracts; Novomedix has no subcontractor engagement.
Activity has accelerated in 2024–2026 after sparse early work — two awards per year in 2024–2025 compared to one or two per year in prior years. Three awards with combined potential value of $3 million face ultimate completion in the next twenty-four months, presenting recompete risk. Novomedix's combined dollars obligated ($13.2 million) exceed its combined potential value ceiling ($3.3 million) at 398%, indicating significant prior-year funding above initial contract ceilings or multiple award cycles per program. Performance of work is located in San Diego, California, with research spanning preclinical models (rodent fibrosis and cancer models) and patient-derived cell culture validation.
Quick answers
Is Novomedix LLC registered in SAM.gov?
Yes. Novomedix LLC's SAM.gov registration is active through May 7, 2027.
What is Novomedix LLC's CAGE code?
Novomedix LLC's CAGE code is 4C2X1, and its Unique Entity ID (UEI) is XQYMHKGDMU75.
How much has Novomedix LLC received in federal contracts?
Federal contracts obligated $2,977,013 to Novomedix LLC in fiscal year 2025.
How does Novomedix LLC rank among federal contractors?
Novomedix LLC ranked #66 in PSC AN12 in FY2025.
What is Novomedix LLC's most recent federal award?
Novomedix LLC's most recent federal grant award is Novel small molecule for the prevention and treatment of DMD cardiomyopathy (R43HL182659), from National Heart Lung and Blood Institute (NIH), on September 1, 2026.
On GovTribe
See Novomedix LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors